- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory multiple myeloma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 302KB)
Selinexor – March 2022
Selinexor (RR MM): Tablet 20 mg; Xpovio®
Last updated
30 May 2025